ROBERT REITER, MD
Urology in Los Angeles, CA
License number
California G67515
Category
Radiology
Type
Urology
Address
Address
10833 Le Conte Ave., Los Angeles, CA 90095
Phone
(310) 794-7700
(310) 206-5343 (Fax)
(310) 206-6766
(310) 206-5343 (Fax)
(310) 206-6766
Personal information
See more information about ROBERT REITER at radaris.comName
Address
Phone
49266 Black Mountain Ct, Aguanga, CA 92536
5974 E Dwight Way, Fresno, CA 93727
9524 Vista Hills Pl, Lakeside, CA 92040
PO Box 884, Pasadena, CA 91102
800 Heinz Ave STE 9, Berkeley, CA 94710
Organization information
See more information about ROBERT REITER at bizstanding.comRobert Reiter
10833 Le Conte Ave, Los Angeles, CA 90095
Industry:
Medical Doctor's Office, Offices and Clinics of Medical Doctors, Nsk
Medical Doctors:
Robert Reiter (Medical Doctor),Robert Kleinman Md Medical Doctor, inactive
Robert Reiter MD
220 Medical Plz, Los Angeles, CA 90095
Industry:
Urologist
Site:
Phone:
(310) 825-5088 (Phone)
Robert Evan Reiter
Robert Reiter MD
10833 Le Conte Ave, Los Angeles, CA 90095
Categories:
Urology Physicians & Surgeons
Phone:
(310) 794-7224 (Phone)
Professional information
Novel Diagnostic And Therapeutic Targets Associated With Or Regulated By N-Cadherin Expression And/Or Epithelial To Mesenchymal Transition (Emt) In Prostate Cancer And Other Malignancies
US Patent:
2013013, May 30, 2013
Filed:
Feb 1, 2011
Appl. No.:
13/576629
Inventors:
Robert E. Reiter - Los Angeles CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
C12Q 1/68
US Classification:
506 2, 435 612, 435 611, 435 792, 435 71
Abstract:
The present invention provides methods of diagnosing a cancer or providing a prognosis for a cancer by analyzing the level of expression of a marker that is a downstream target of N-cadherin.
Robert E Reiter, Los Angeles CA
Specialties:
Urologist
Address:
10833 Le Conte Ave, Los Angeles, CA 90095
Board certifications:
American Board of Urology Certification in Urology*
Mice Models Of Human Prostate Cancer
US Patent:
6828471, Dec 7, 2004
Filed:
Jan 30, 2002
Appl. No.:
10/062925
Inventors:
Charles L. Sawyers - Los Angeles CA
Karen A. Klein - Los Angeles CA
Owen N. Witte - Sherman Oaks CA
Robert E. Reiter - Los Angeles CA
Karen A. Klein - Los Angeles CA
Owen N. Witte - Sherman Oaks CA
Robert E. Reiter - Los Angeles CA
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A01K 6700
US Classification:
800 10, 800 8, 800 18
Abstract:
The present invention provides an immune deficient mouse having a human prostate xenograft of locally advanced or metastatic prostate cancer and uses thereof.
Psca: Prostate Stem Cell Antigen And Uses Thereof
US Patent:
6825326, Nov 30, 2004
Filed:
Aug 21, 2001
Appl. No.:
09/934773
Inventors:
Robert E. Reiter - Los Angeles CA
Owen N. Witte - Sherman Oaks CA
Owen N. Witte - Sherman Oaks CA
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
C07K 1600
US Classification:
53038885, 5303873, 5303917, 4241781
Abstract:
The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.
Engineered Anti-Prostate Stem Cell Antigen (Psca) Antibodies For Cancer Targeting
US Patent:
2009031, Dec 17, 2009
Filed:
Mar 20, 2007
Appl. No.:
12/293860
Inventors:
Anna M. Wu - Sherman Oaks CA, US
Robert E. Reiter - Los Angeles CA, US
Robert E. Reiter - Los Angeles CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 49/00, C07K 16/30, A61K 49/04, G01N 33/574, A61K 39/395
US Classification:
424 91, 5303873, 424 149, 424 94, 435 723, 4241331
Abstract:
The invention provides novel humanized antibody fragments that specifically bind prostate cell-surface antigen (PSCA), a protein which is overexpressed in variety of cancers, including prostate, bladder, and pancreatic cancer. Methods are provided for the use of the compositions of the invention for the treatment of cancer, diagnosis of cancer, to provide a prognosis of cancer progression, and for cancer imaging.
Methods For Detecting The Presence Of A Psca Protein Using Psca Antibodies
US Patent:
6261789, Jul 17, 2001
Filed:
Feb 17, 1999
Appl. No.:
9/251835
Inventors:
Robert E. Reiter - Los Angeles CA
Owen N. Witte - Sherman Oaks CA
Owen N. Witte - Sherman Oaks CA
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
G01N 3353
US Classification:
435 723
Abstract:
The invention provides methods for detecting the presence of a PSCA protein comprising contacting the sample with PSCA antibodies designated 1G8 (ATCC No. HB-12612), 2A2 (ATCC No. HB-12613), 2H9 (ATCC No. HB-12614), 3C5 (ATCC No. HB-12616), 3E6 (ATCC No. HB12618), 3G3 (ATCC No. HB-12615), or 4A10 (ATCC No. HB-12617).
Humanized Anti-Prostate Stem Cell Antigen Monoclonal Antibody
US Patent:
8404817, Mar 26, 2013
Filed:
Dec 1, 2011
Appl. No.:
13/308783
Inventors:
Mark A. Sherman - Pasadena CA, US
Anna M. Wu - Sherman Oaks CA, US
Robert E. Reiter - Los Angeles CA, US
Anna M. Wu - Sherman Oaks CA, US
Robert E. Reiter - Los Angeles CA, US
Assignee:
City of Hope - Duarte CA
The Regents of the University of California - Oakland CA
The Regents of the University of California - Oakland CA
International Classification:
C12P 21/08
US Classification:
5303873, 5303911, 5303913, 5303917
Abstract:
Prostate stem cell antigen (PSCA) is expressed in the majority of prostate cancer patients, making it an ideal target for cancer immunotherapy. Murine monoclonal antibody 1G8 binds to PSCA with nanomolar affinity, but its efficacy as a therapeutic agent is limited by the generation of a HAMA response. The present invention discloses humanized 1G8 antibodies in which the majority of the mouse-derived epitopes have been removed. These humanized antibodies bind PSCA with high affinity and specificity, and have been shown to reduce human bladder tumor take in a nude mouse model. These characteristics make the humanized antibodies of the present invention attractive agents for the treatment and detection of tumors expressing PSCA.
N-Cadherin And Ly6 E: Targets For Cancer Diagnosis And Therapy
US Patent:
2009013, May 21, 2009
Filed:
Mar 21, 2007
Appl. No.:
12/294023
Inventors:
Robert E. Reiter - Los Angeles CA, US
Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - OAKLAND CA
International Classification:
A61K 39/395, C12Q 1/68, A61K 31/7105
US Classification:
4241381, 435 6, 514 44
Abstract:
The present invention provides methods of diagnosis, providing a prognosis and a therapeutic target for the treatment of cancers that overexpress N-cadherin and Ly6-E, including prostrate and bladder cancers. The invention further provides methods of drug discovery to identify pharmaceutical agents that inhibit or prevent the binding of N-cadherin and Ly6-E to its receptor, which are useful when used alone or in combination with known chemotherapeutics, immunotherapeutics, and radiotherapy for the reversal of resistance, tumor progression, and metastasis of cancers associated with the overexpession of N-cadherin and Ly6-E.
Humanized Anti-Prostate Stem Cell Antigen Monoclonal Antibody
US Patent:
8088908, Jan 3, 2012
Filed:
May 10, 2006
Appl. No.:
11/432304
Inventors:
Mark A. Sherman - Pasadena CA, US
Anna M. Wu - Sherman Oaks CA, US
Robert E. Reiter - Los Angeles CA, US
Anna M. Wu - Sherman Oaks CA, US
Robert E. Reiter - Los Angeles CA, US
Assignee:
City of Hope - Duarte CA
The Regents of the University of California - Oakland CA
The Regents of the University of California - Oakland CA
International Classification:
C07H 21/04
US Classification:
536 2353, 536 231
Abstract:
Prostate stem cell antigen (PSCA) is expressed in the majority of prostate cancer patients, making it an ideal target for cancer immunotherapy. Murine monoclonal antibody 1G8 binds to PSCA with nanomolar affinity, but its efficacy as a therapeutic agent is limited by the generation of a HAMA response. The present invention discloses humanized 1G8 antibodies in which the majority of the mouse-derived epitopes have been removed. These humanized antibodies bind PSCA with high affinity and specificity, and have been shown to reduce human bladder tumor take in a nude mouse model. These characteristics make the humanized antibodies of the present invention attractive agents for the treatment and detection of tumors expressing PSCA.
Mouse Models Of Human Prostate Cancer
US Patent:
7122714, Oct 17, 2006
Filed:
Feb 4, 2002
Appl. No.:
10/067705
Inventors:
Charles L. Sawyers - Los Angeles CA, US
Karen A. Klein - Los Angeles CA, US
Owen N. Witte - Sherman Oaks CA, US
Robert E. Reiter - Los Angeles CA, US
Karen A. Klein - Los Angeles CA, US
Owen N. Witte - Sherman Oaks CA, US
Robert E. Reiter - Los Angeles CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A01K 67/00, A01N 63/00, A01N 65/00, A01K 67/027
US Classification:
800 10, 800 8, 800 9, 800 14, 800 18, 424 931
Abstract:
The present invention provides an immune deficient mouse having a human prostate xenograft of locally advanced or metastatic prostate cancer and uses thereof.